Related Experiment Video
Updated: Jun 20, 2026

Synovial Fluid Analysis to Identify Osteoarthritis
Published on: October 20, 2022
Clinical Factors for Predicting Synovial Hypertrophy in Early Haemophilic Arthropathy on Prophylaxis: A
Takeo Abe1, Yusuke Inagaki2, Chie Ogita1
1Department of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
Introduction:
Early identification of synovial hypertrophy is critical for preventing irreversible changes in haemophilic arthropathy (HA). Although prophylaxis has improved joint outcomes, it remains unclear which patients and joints in early HA should be prioritised for musculoskeletal ultrasound (MSKUS) screening.
Aim:
To identify the predictors of synovial hypertrophy at the patient and joint levels in early HA.
Methods:
We enrolled patients with haemophilia aged 6-49 years with mild joint damage (Arnold-Hilgartner grades I-III). Elbows, knees and ankles were examined using MSKUS. Patient-level factors included age, body mass index, haemophilia characteristics, adherence and activity. Joint-level factors included symptoms, recent bleeding, physical findings and radiographic scores. Logistic regression was applied to patient-level predictors and mixed-effects models to joint-level predictors.
Results:
In total, 203 joints from 40 patients were evaluated; synovial hypertrophy was identified in 82 joints (34 patients), most frequently in the knees (54.5%), followed by the elbows (38.9%) and ankles (22.2%). Adult age was the only significant patient-level predictor of synovial hypertrophy (odds ratio, 5.2; p = 0.001). At the joint level, no examined factors were significantly associated with synovial hypertrophy. Among asymptomatic joints, 37.9% demonstrated synovial hypertrophy (23.7% in paediatric patients vs. 56.9% in adults), with elbow involvement showing no significant age-related differences (34.4% vs. 40.7%, p = 0.79).
Conclusions:
Patient- and joint-specific findings alone are insufficient to predict synovial hypertrophy. MSKUS may be used routinely to enhance early detection in patients with HA on prophylaxis. Elbow synovial hypertrophy warrants attention from paediatric patients as one of the earliest stages of the disease.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Development of the Limb Synovial Joints
The mesenchymal stem cells differentiate into chondrocytes that form the hyaline cartilage, and later the cartilaginous model of the bone. This model further transforms into a bone. This process is known as endochondral ossification.
During development, the limbs...
Rheumatic Heart Disease I: Introduction